unit sales with volume-based pricing

negotiated with rebates

75–80%

product sales

Direct sales force engagement and digital channels

institutional (payers, healthcare systems)

consumer (direct-to-patient)

manufacturer

collaborator/licensor

High

5.0% OpEx / Revenue (Highly Efficient)

Global

Very High

Low

Yes

High

Moderate

Moderate

No

Low

22.9% Return on Assets (Strong)

Mixed

Low

1.15x Total Debt / Equity (Elevated leverage)

Low intensity; The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Sublinear

High

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.25 (HIL — ~25% of characteristic roles agent-automatable)

Low intensity; commodities: active pharmaceutical ingredients / key starting materials (semi-processed chemical intermediates), petrochemical-derived medical resins (polypropylene, PVC), titanium and cobalt-chromium alloys, borosilicate pharmaceutical glass, liquid helium, stainless steel; geopolitical: The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0000059478

LLY

High

active_enforcement_matters,antitrust_exposure_flag,business_model_type_primary,business_model_type_secondary,capital_return_posture,channel_inventory_exposure,churn_vulnerability_index,currency_risk_exposure,customer_acquisition_metric,customer_segment_primary,customer_segment_secondary,cyber_framework_alignment,cyber_incident_materiality,cyber_oversight_body,data_sovereignty_risk,employee_headcount,franchise_compliance_risk,geographic_footprint,geopolitical_supply_exposure,headcount_cost_structure,hedging_program_scope,howey_test_risk_index,interest_rate_sensitivity,international_expansion_readiness,key_person_dependency,liquidity_sufficiency_assertion,marginal_cost_of_growth,market_structure,monetization_vector,named_competitors,network_effect_present,pricing_architecture,pricing_power_rating,product_revenue_concentration,purchase_commitment_rigidity,recession_resistance_tier,regulatory_burden_tier,revenue_model_type,seasonality_pattern,supply_chain_dependency,switching_cost_profile,trade_restriction_exposure,vendor_lock_dependency_score

0

6

-31828

2026-08-17

2026-10-03T13:38|activist_13d_count_1y,activist_last_13d_date,blockholder_13g_count_1y,insider_buys_6m,insider_last_transaction_date,insider_net_shares_6m,insider_sells_6m

Not disclosed in filing

Not disclosed in filing

Not explicitly named; filing discusses competitive landscape in general

Fragmented

Mounjaro and Zepbound = 56% of total revenue in 2025

Dividend+Buyback; FY2025: $6.00/share dividends; $4.1B share repurchases

Moderate - tariffs and China supply chain exposure; no dollar amount quantified

Affirmed

High - distribution through three major wholesalers

Yes - multiple matters disclosed but not named as current consent orders

High - approximately $10 billion in non-cancellable commitments

No

NIST CSF

Audit committee; full board monitors risks

Moderate - EUR, JPY, CNY, GBP; no specific revenue % disclosed

FX forwards/options for transactional exposures; no commodity hedging disclosed

0

7

none in window

unit sales with volume-based pricing

negotiated with rebates

75–80%

product sales

Direct sales force engagement and digital channels

institutional (payers, healthcare systems)

consumer (direct-to-patient)

manufacturer

collaborator/licensor

High

5.0% OpEx / Revenue (Highly Efficient)

Global

Very High

Low

Yes

High

Moderate

Moderate

No

Low

22.9% Return on Assets (Strong)

Mixed

Low

1.15x Total Debt / Equity (Elevated leverage)

Low intensity; The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Sublinear

High

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.25 (HIL — ~25% of characteristic roles agent-automatable)

Low intensity; commodities: active pharmaceutical ingredients / key starting materials (semi-processed chemical intermediates), petrochemical-derived medical resins (polypropylene, PVC), titanium and cobalt-chromium alloys, borosilicate pharmaceutical glass, liquid helium, stainless steel; geopolitical: The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0000059478

LLY

High

active_enforcement_matters,antitrust_exposure_flag,business_model_type_primary,business_model_type_secondary,capital_return_posture,channel_inventory_exposure,churn_vulnerability_index,currency_risk_exposure,customer_acquisition_metric,customer_segment_primary,customer_segment_secondary,cyber_framework_alignment,cyber_incident_materiality,cyber_oversight_body,data_sovereignty_risk,employee_headcount,franchise_compliance_risk,geographic_footprint,geopolitical_supply_exposure,headcount_cost_structure,hedging_program_scope,howey_test_risk_index,interest_rate_sensitivity,international_expansion_readiness,key_person_dependency,liquidity_sufficiency_assertion,marginal_cost_of_growth,market_structure,monetization_vector,named_competitors,network_effect_present,pricing_architecture,pricing_power_rating,product_revenue_concentration,purchase_commitment_rigidity,recession_resistance_tier,regulatory_burden_tier,revenue_model_type,seasonality_pattern,supply_chain_dependency,switching_cost_profile,trade_restriction_exposure,vendor_lock_dependency_score

0

6

-31828

2026-08-17

2026-10-03T13:38|activist_13d_count_1y,activist_last_13d_date,blockholder_13g_count_1y,insider_buys_6m,insider_last_transaction_date,insider_net_shares_6m,insider_sells_6m

Not disclosed in filing

Not disclosed in filing

Not explicitly named; filing discusses competitive landscape in general

Fragmented

Mounjaro and Zepbound = 56% of total revenue in 2025

Dividend+Buyback; FY2025: $6.00/share dividends; $4.1B share repurchases

Moderate - tariffs and China supply chain exposure; no dollar amount quantified

Affirmed

High - distribution through three major wholesalers

Yes - multiple matters disclosed but not named as current consent orders

High - approximately $10 billion in non-cancellable commitments

No

NIST CSF

Audit committee; full board monitors risks

Moderate - EUR, JPY, CNY, GBP; no specific revenue % disclosed

FX forwards/options for transactional exposures; no commodity hedging disclosed

0

7

none in window